SCHEMBL3769508

SCHEMBL3769508

O=C(NCc1ncc[nH]1)c1cc[c]cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.49
FPR2 P25090 1/20 0.49
GAA P10253 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGAV P06756 1/20 0.42
ITGA2B P08514 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
KLK1 P06870 1/20 0.41
KLK5 Q9Y337 1/20 0.41
SLC40A1 Q9NP59 1/20 0.40
JAK2 O60674 1/20 0.39
FLT3 P36888 1/20 0.39
SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31188529 0.85 GAA (0.60) ROCK2FPR2GAASMN1; SMN2TAAR1
SCHEMBL12459652 0.82 ROCK2 (0.52) ROCK2FPR2GAASMN1; SMN2ADORA3
SCHEMBL14817907 0.82 ROCK2 (0.52) ROCK2FPR2SMN1; SMN2ADORA3ADORA2A
SCHEMBL16161628 0.80 FPR2 (0.71) ROCK2FPR2SMN1; SMN2ADORA3ADORA2A
SCHEMBL18617522 0.80 ROCK2 (0.50) ROCK2FPR2GAASMN1; SMN2ADORA3
SCHEMBL31680532 0.78 TAAR1 (0.55) ROCK2FPR2GAASMN1; SMN2TAAR1
SCHEMBL21335657 0.78 PLK1 (0.50) ROCK2FPR2GAASMN1; SMN2ADORA3
SCHEMBL20671963 0.77 ROCK2 (0.47) ROCK2FPR2GAASMN1; SMN2ADORA3
SCHEMBL3769502 0.76 FPR2 (0.46) ROCK2FPR2GAASMN1; SMN2ADORA3
SCHEMBL6451096 0.74 FPR2 (0.55) ROCK2FPR2GAASMN1; SMN2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ROCK2 977/4885FPR2 2951/4885GAA 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.